Inactivated Coxsackievirus A10 Experimental Vaccines Protect Mice Against Lethal Viral Challenge

Chaoyun Shen,Qingwei Liu,Yu Zhou,Zhiqiang Ku,Lili Wang,Ke Lan,Xiaohua Ye,Zhong Huang
DOI: https://doi.org/10.1016/j.vaccine.2016.08.033
IF: 4.169
2016-01-01
Vaccine
Abstract:Coxsackievirus A10 (CVA10) has become one of the major causative agents of hand, foot and mouth disease (HFMD). It is now recognized that CVA10 should be targeted for vaccine development. We report here that β-propiolactone inactivated whole-virus based CVA10 vaccines can elicit protective immunity in mice. We prepared two inactivated CVA10 experimental vaccines derived from the prototype strain CVA10/Kowalik and from a clinical isolate CVA10/S0148b, respectively. Immunization with the experimental vaccines elicited CVA10-specific serum antibodies in mice. The antisera from vaccinated mice could potently neutralize in vitro infection with either homologous or heterologous CVA10 strains. Importantly, passive transfer of the anti-CVA10 sera protected recipient mice against CVA10/Kowalik or CVA10/S0148b infections. Moreover, active immunization with the inactivated vaccines also conferred protection against homologous and heterologous infections in mice. Collectively, our results demonstrate the proof-of-concept for inactivated whole-virus based CVA10 vaccines.
What problem does this paper attempt to address?